Liquidia Stock Craters After Losing Patent Case to United Therapeutics

A court ruled against Liquidia in a patent infringement case brought by United Therapeutics, finding for the rival company on two separate claims. Liquidia shares dropped sharply on the news, which wire reports described as the stock 'cratering.' The ruling matters because it could block or delay Liquidia products that compete with United Therapeutics' offerings, undercutting the investment case that had drawn shareholders to the smaller drugmaker. United Therapeutics, by contrast, protects a competitive position it has defended through litigation. It is not yet clear whether Liquidia will appeal the decision or what the practical timeline is for any resulting product restrictions. Investors will be watching for Liquidia's official response and any guidance on how the ruling affects its commercial plans.